Analysts cited data from a phase one study showing the highest dose of Amgen's MariTide was linked to roughly 4% loss of bone ...

Amgen stock tumbled late Tuesday on a report that its high-profile weight-loss shot, MariTide, could be linked to bone ...

Amgen Inc.‘s AMGN stock dropped over 7% on Tuesday following revelations about bone density loss in early trials of its ...

On Tuesday, a tiny shred of data on Amgen’s lead obesity candidate — not yet verified — erased $12 billion in market value.

Jefferies reviewed public data from the Phase 1 trial of AMG-133 showing additional measurements of bone density from obesity patients, which ...

Amgen ( AMGN 1.68%), a leader in biotechnology, released its third-quarter 2024 financial results on Oct. 30. The company ...

These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through ...

Amgen (NASDAQ: AMGN) Q3 2024 Earnings Call Oct 30, 2024, 4:30 p.m. ET ...

Amgen (AMGN) and AstraZeneca (AZN) announced top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with ...

Scientists at deCODE genetics, a subsidiary of Amgen, published a study today in Nature Communications that sheds light on ...

Biotechnology firm Amgen has been awarded menopause-friendly employer accreditation as part of its aim to ensure all of its ...

New study from deCODE genetics/Amgen highlights the importance of BMI in pathogenesis of disease, suggesting that reducing BMI alone could lower the risk of several diseases. Scientists at deCODE ...